Obicetrapib and CETP inhibition: An exception to the rule?

IF 11.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-08-08 DOI:10.1016/j.medj.2025.100780

Bertrand Cariou, Philippe Moulin

引用次数: 0

Abstract

Obicetrapib is the latest CETP inhibitor, a drug class blocking lipid transfer between LDL and HDL. In two phase 3 trials, BROADWAY¹ and TANDEM,² obicetrapib alone or with ezetimibe lowered LDL-C, apolipoprotein B, and Lp(a) levels in patients with high cardiovascular risk. Given previous CETP inhibitor failures, results of the ongoing cardiovascular outcome study are needed to confirm obicetrapib's cardiovascular benefits.

查看原文本刊更多论文

Obicetrapib和CETP抑制：规则的例外？

Obicetrapib是最新的CETP抑制剂，一种阻断LDL和HDL之间脂质转移的药物。在BROADWAY1和TANDEM两项3期试验中，obicetrapib单独或与依折替米贝联合可降低心血管高危患者的LDL-C、载脂蛋白B和Lp(a)水平。鉴于先前CETP抑制剂失败，需要正在进行的心血管结局研究的结果来证实obicetrapib的心血管益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.